ArticleVaccine: X2025
Cross-country analysis on HPV vaccination behaviors among health workers and parents: a qualitative report from seven middle-income countries.
Article in Vaccine: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This article presents a cross-country analysis of qualitative research reports on the barriers and drivers of HPV vaccination-related behavior among parents and health workers in seven middle-income countries using the COM-B theoretical framework. Four reports are from countries that had already introduced the HPV vaccine - Georgia, Moldova, Turkmenistan, and Uzbekistan, while the other three reports are from Kazakhstan, Kosovo, and Tajikistan which were preparing for HPV vaccine introduction in 2023 and 2024. Results: The cross-country analysis revealed that health workers (HWs), especially specialists like gynecologists and oncologists, were viewed as trusted sources of vaccination information by both parents and HWs. However, HWs faced gaps in HPV vaccine knowledge and communication skills, and these gaps persisted in some form even after training was conducted in countries that had already introduced the HPV vaccine. In addition, these specialists were not always included when training sessions were conducted with family doctors and nurses in preparation for the vaccine's introduction. Parents also experience knowledge gaps, safety concerns, and lack of trust. Parents across countries shared concerns related to HPV vaccine safety and effectiveness and were often exposed to misconceptions or misinformation through media and social networks. This was compounded by the lack of a strong and confident recommendation from HWs and poor patient-provider communication. Conclusions: The analyzed reports highlighted the need for tailored, multi-faceted interventions that account for locally specific issues, influencers, and target groups. Two prominent recommendations posited in the reports were: 1) engaging parents and addressing their concerns at the community level, and 2) ensuring HPV vaccine confidence through HW training and engagement, especially for specialists, and providing access to evidence-based information for HWs and others who influence vaccine acceptance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.